



PUBLIC HEALTH

**ALWAYS WORKING FOR A SAFER AND
HEALTHIER WASHINGTON**

New HIV Prevention Developments

Dave Kern
Manager

DOH HIV and Adult Viral Hepatitis Prevention Section



For persons with disabilities, this document is available on request in other formats.
To submit a request, please call 1-800-525-0127 (TDD/TTY 1-800-833-6388).

NEW DEVELOPMENTS

- Use of Truvada for pre-exposure prophylaxis (PrEP)
- Home-based rapid HIV testing

PrEP

- New development: FDA approved the use of Truvada for PrEP
- What is PrEP?
 - HIV negative people who are at high risk take antiretroviral medication daily to try to lower their chances of becoming infected with HIV if they are exposed to it.
- What does the science say?
 - *TDF2* study found that once-daily Truvada reduced the risk of acquiring HIV infection by roughly 63 percent among study participants (uninfected heterosexual men and women).
 - Among participants who consistently took medications (i.e., didn't stop), risk of HIV infection was reduced by 78 percent.
 - *Partners PrEP* found that two separate regimens – Truvada and tenofovir alone – significantly reduced HIV transmission in sero-discordant couples.

PrEP (continued)

- Other considerations
 - CDC has already developed guidance for PrEP.
 - Individuals are already using PrEP (anecdotal evidence).
 - Since the FDA approved Truvada for PrEP, insurance companies will likely pay for it in the future.

HOME-BASED HIV TESTING

- New development: FDA panel approved the use of OraQuick for rapid home-based HIV testing
- What is OraQuick?
 - OraQuick uses a mouth swab to detect HIV antibodies within 20 minutes.
- What does the science say?
 - OraQuick correctly detected HIV in those carrying the virus 93% of the time.
 - FDA estimates that OraQuick would correctly identify 45,000 HIV-positive persons per year, while missing about 3,800.
 - Test could prevent 4,000 new transmission annually (dependent on how many persons use the test).
- Other considerations
 - OraQuick is the first OTC rapid HIV test approved by the FDA.
 - Negative readings do not automatically mean a person is HIV-negative.
 - For those testing positive, what must be available to them?

DISCUSSION

- What opportunities exist because of these developments?
- What cautions should be considered as these developments make their way into the mainstream?
- How should DOH prepare for these developments?

PUBLIC HEALTH
ALWAYS WORKING FOR A SAFER AND
HEALTHIER WASHINGTON

decision-making